Biologic treatments in Sjögren's syndrome

Bowman, Simon; Barone, Francesca

doi:10.1016/j.lpm.2012.05.024

Cited by 15 publications

(8 citation statements)

References 137 publications

(139 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypogammaglobulinemia is more likely associated with repeated courses of RTX treatment, although is still not clearly established if the decrease of immunoglobulins, reported in these patients, may be associated with higher risk of infection [50].…”

Section: Retreatment and Safetymentioning

confidence: 91%

Use of Rituximab in the Management of Sjögren’s Syndrome

Carubbi

Alunno

Cipriani

et al. 2015

Curr Treat Options in Rheum

View full text Add to dashboard Cite

Section: Retreatment and Safetymentioning

confidence: 91%

Use of Rituximab in the Management of Sjögren’s Syndrome

Carubbi

Alunno

Cipriani

et al. 2015

Curr Treat Options in Rheum

View full text Add to dashboard Cite

“…The pathogenesis of SjS still remains elusive with previous emphasis on the pathogenetic role of T cells. Current data indicates the substantial contribution of B-cells in the immunopathogenesis of SjS (1). B-cells may constitute germinal centers in affected salivary glands.…”

Section: Introductionmentioning

confidence: 90%

“…The serum level of soluble sBAFF is elevated in SjS patients. In addition, there is increased expression of BAFF on blood mononuclear cells (1).…”

Section: Introductionmentioning

confidence: 99%

Increase of Intracellular BAFF in B Cells of Sjögren’s Patients Is Not Affected by Decrease of BAFFR

Krejsek

Koláčková

Lindrová

et al. 2015

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

Summary:The presence of a broad spectrum of autoantibodies in Sjögren's syndrome (SjS) patients is the result of abnormal B-cell regulation that can be at least partially explained by abnormal BAFF/BAFFR regulation. The objective of this study was to determine both membrane and intracellular expression of BAFF/BAFFR in monocytes and B-cells in peripheral blood of 19 primary Sjögren's syndrome patients and 20 healthy controls using flow cytometry. We also measured sBAFF in serum. Compared to healthy controls, both surface and intracellular expression of BAFF was significantly increased in monocytes and B-cells of SjS patients. Also serum sBAFF level was elevated. Expression of BAFFR on B-cells of SjS patients was surprisingly decreased, but there was no clear increase or decrease within monocytes. Our results indicate that activated monocytes communicate with B-cells via BAFF and BAFFR, so that B-cells are stimulated, but BAFF is also produced to stimulate cells in autocrine way. The decrease of BAFFR expression in SjS patients suggests that there is the mechanism that attempts to take over in order to balance the high level of BAFF.

show abstract

“…Current therapy for dryness is principally symptomatic. The greatest experience with treatment of Sjogren's syndrome is with rituximab, an anti-CD20 (expressed on a subset of B-cells) monoclonal antibody [22]. Figure 7.…”

mentioning

confidence: 99%

“…Patients unable to tolerate such an operation may consider one of the many less invasive options including Gamma Knife radiosurgery (Table 1). Eagles syndrome, TMJ and Trigeminal neuralgia can co-exist with glossopharyngeal neuritis, and mask the diagnosis, or be mistaken for it [16,17,19,22,23].…”

mentioning

confidence: 99%

Facial pain from various sources-diagnoses and differential diagnoses

Hendler¹

2017

Dent Oral Craniofac Res

View full text Add to dashboard Cite

Biologic treatments in Sjögren's syndrome

Cited by 15 publications

References 137 publications

Use of Rituximab in the Management of Sjögren’s Syndrome

Use of Rituximab in the Management of Sjögren’s Syndrome

Increase of Intracellular BAFF in B Cells of Sjögren’s Patients Is Not Affected by Decrease of BAFFR

Facial pain from various sources-diagnoses and differential diagnoses

Contact Info

Product

Resources

About